UNASSIGNED: A hospital database was used to extract data on IVF-ET cases from January 2020 to September 2021. The levels of female reproductive hormones, including estradiol (E2), luteinizing hormone (LH), progesterone (P), and follicle-stimulating hormone (FSH), were initially evaluated at baseline, the day of the trigger, the day after the trigger, and the day of oocyte retrieval. The relative change in E2, LH, P, FSH between time point 1 (the day of trigger and baseline) and time point 2 (the day after the trigger and day on the trigger) was defined as E2_RoV1/2, LH_RoV1/2, P_RoV1/2, and FSH_RoV1/2, respectively. Univariable and multivariable regression were performed to screen the peri-trigger FRHs for the prediction of oocyte maturation.
UNASSIGNED: A total of 118 patients were enrolled in our study. Univariable analysis revealed significant associations between E2_RoV1 and the rate of MII oocytes in the GnRH-agonist protocol group (p < 0.05), but not in the GnRH-antagonist protocol group. Conversely, P_RoV2 emerged as a potential predictor for the rate of MII oocytes in both protocol groups (p < 0.05). Multivariable analysis confirmed the significance of P_RoV2 in predicting oocyte maturation rate in both groups (p < 0.05), while the association of E2_RoV1 was not significant in either group. However, within the subgroup of high P_RoV2 in the GnRH-agonist protocol group, association was not observed to be significant. The C-index was 0.83 (95% CI [0.73-0.92]) for the GnRH-agonist protocol group and 0.77 (95% CI [0.63-0.90]) for the GnRH-antagonist protocol group. The ROC curve analysis further supported the satisfactory performance of the models, with area under the curve (AUC) values of 0.79 for the GnRH-agonist protocol group and 0.81 for the GnRH-antagonist protocol group.
UNASSIGNED: P_RoV2 showed significant predictive value for oocyte maturation in both GnRH-agonist and GnRH-antagonist protocol groups, which enhances the understanding of evaluating oocyte maturation and inform individualized treatment protocols in controlled ovarian hyperstimulation during IVF-ET for normal ovarian reserve patients.
■使用医院数据库提取2020年1月至2021年9月的IVF-ET病例数据。女性生殖荷尔蒙的水平,包括雌二醇(E2),黄体生成素(LH),孕酮(P),和卵泡刺激素(FSH),最初是在基线时评估的,触发的那天,触发后的第二天,和取卵日。E2、LH、P,时间点1(触发日期和基线)和时间点2(触发日期之后和触发日期之后)之间的FSH分别定义为E2_RoV1/2、LH_RoV1/2、P_RoV1/2和FSH_RoV1/2。进行单变量和多变量回归来筛选周围触发FRHs以预测卵母细胞成熟。
■共有118名患者参加了我们的研究。单变量分析显示E2_RoV1与GnRH激动剂组的MII卵母细胞比率之间存在显著关联(p<0.05),但在GnRH拮抗剂方案组中没有。相反,P_RoV2作为两个方案组中MII卵母细胞率的潜在预测因子(p<0.05)。多变量分析证实P_RoV2在预测两组卵母细胞成熟率中的意义(p<0.05)。而E2_RoV1在两组中的相关性均不显著。然而,在GnRH激动剂方案组中的高P_RoV2亚组内,没有观察到相关性是显著的。GnRH激动剂方案组的C指数为0.83(95%CI[0.73-0.92]),GnRH拮抗剂方案组为0.77(95%CI[0.63-0.90])。ROC曲线分析进一步支持了模型的令人满意的性能,GnRH激动剂方案组的曲线下面积(AUC)值为0.79,GnRH拮抗剂方案组为0.81。
■P_RoV2对GnRH激动剂和GnRH拮抗剂方案组的卵母细胞成熟均显示出显著的预测价值,这增强了对评估卵母细胞成熟的理解,并为正常卵巢储备患者在IVF-ET期间控制性超促排卵的个体化治疗方案提供了信息。